Journal of Veterinary Clinics (한국임상수의학회지)

The Korean Society of Veterinary Clinics (한국임상수의학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical Application of Imatinib Mesylate in a Case of Feline Cutaneous Mast Cell Tumor: Clinical Progress, Histopathological, and Immunohistochemical Findings

  • Jang, Hyo-Mi (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University) ;
  • Song, Joong-Hyun (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University) ;
  • Hwang, Tae-Sung (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University) ;
  • Lee, Hee-Chun (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University) ;
  • Yu, Do-Hyeon (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University) ;
  • Sur, Jung-Hyang (Department of Pathobiology, Small Animal Tumor Diagnostic Center, College of Veterinary Medicine, Konkuk University) ;
  • Kang, Byeong-Teck (Laboratory of Veterinary Dermatology and Neurology, College of Veterinary Medicine, Chungbuk National University) ;
  • Jo, Yang-Rae (Joyangrae Animal Medical Center) ;
  • Jung, Dong-In (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University)
  • Received : 2017.09.18
  • Accepted : 2017.12.13
  • Published : 2017.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

A 1.5-year-old neutered male domestic short hair cat was presented with multiple nodular mass, and suspected mast cell tumor on the surface of the right ear, accompanied by submandibular lymph node involvement. Histopathological Examinations and KIT (CD117) immunohistochemical staining was performed after the surgical resection of the entire right ear pinna. This patient was diagnosed with an anaplastic mast cell tumor with a diffuse positive cytoplasmic expression of KIT. Imatinib mesylate was prescribed after surgical resection; the patient presented without recurrence or metastasis for 2 years. Mild leukopenia was observed as the only side effect of imatinib mesylate during medication.

Keywords

References

  1. Antognoni M, Spaterna A, Lepri E, Fruganti A, Laus F. Characteristic clinical, haematological and histopathological findings in feline mastocytoma. Vet Res Commun 2003; 27: 727-730. https://doi.org/10.1023/B:VERC.0000014258.64713.ca
  2. Blackwood L, Murphy S, Buracco P, De Vos J, Fornel-Thibaud D, Hirschberger J, Kessler M, Pastor J, Ponce F, Savary-Bataille K. European consensus document on mast cell tumours in dogs and cats. Vet Comp Oncol 2012; 10: e1-e29. https://doi.org/10.1111/j.1476-5829.2012.00341.x
  3. Chastain C, Turk M, O'Brien D. Benign cutaneous mastocytomas in two litters of Siamese kittens. J Am Vet Med Assoc 1988; 193: 959-960.
  4. da Costa RMG, Matos E, Rema A, Lopes C, Pires MA, Gartner F. CD117 immunoexpression in canine mast cell tumours: correlations with pathological variables and proliferation markers. BMC Vet Res 2007; 3: 19. https://doi.org/10.1186/1746-6148-3-19
  5. Daly M, Sheppard S, Cohen N, Nabity M, Moussy A, Hermine O, Wilson H. Safety of masitinib mesylate in healthy cats. J Vet Intern Med 2011; 25: 297-302. https://doi.org/10.1111/j.1939-1676.2011.0687.x
  6. Downing S, Chien MB, Kass PH, Moore PF, London CA. Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs. Am. J Vet Res 2002; 63: 1718-1723. https://doi.org/10.2460/ajvr.2002.63.1718
  7. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993; 92: 1736-1744. https://doi.org/10.1172/JCI116761
  8. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A, Aldanondo I, Sanchez L, Dominguez M, Botana LM. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006; 108: 2366-2372. https://doi.org/10.1182/blood-2006-04-015545
  9. Henry C, Herrera C. Mast cell tumors in cats: clinical update and possible new treatment avenues. J Feline Med Surg 2013; 15: 41-47. https://doi.org/10.1177/1098612X12470343
  10. Isotani M, Tamura K, Yagihara H, Hikosaka M, Ono K, Washizu T, Bonkobara M. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate. Vet Immunol Immunopathol 2006; 114: 168-172. https://doi.org/10.1016/j.vetimm.2006.07.004
  11. Isotani M, Yamada O, Lachowicz JL, Tamura K, Yagihara H, Fujino Y, Ono K, Washizu T, Bonkobara M. Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours. Br J haematol. 2010; 148: 144-153. https://doi.org/10.1111/j.1365-2141.2009.07926.x
  12. Johnson TO, Schulman FY, Lipscomb TP, Yantis LD. Histopathology and biologic behavior of pleomorphic cutaneous mast cell tumors in fifteen cats. Vet Pathol 2002; 39: 452-457. https://doi.org/10.1354/vp.39-4-452
  13. Kiupel M, Webster J, Kaneene J, Miller R, Yuzbasiyan-Gurkan V. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors. Vet Pathol 2004; 41: 371-377. https://doi.org/10.1354/vp.41-4-371
  14. Lachowicz JL, Post GS, Brodsky E. A Phase I Clinical Trial Evaluating Imatinib Mesylate (Gleevec) in Tumor-Bearing Cats. J Vet Intern Med 2005; 19: 860-864. https://doi.org/10.1111/j.1939-1676.2005.tb02778.x
  15. Litster AL, Sorenmo KU. Characterisation of the signalment, clinical and survival characteristics of 41 cats with mast cell neoplasia. J Feline Med Surg 2006; 8: 177-183. https://doi.org/10.1016/j.jfms.2005.12.005
  16. London CA. Tyrosine kinase inhibitors in veterinary medicine. Top Companion Anim Med 2009; 24: 106-112. https://doi.org/10.1053/j.tcam.2009.02.002
  17. London CA, Galli SJ, Yuuki T, Hu Z-Q, Helfand SC, Geissler EN. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol 1999; 27: 689-697. https://doi.org/10.1016/S0301-472X(98)00075-7
  18. London CA, Thamm DH. Mast cell tumors. In: Small Animal Oncology, 5th ed. St. Louis: Elsevier; 2013: 335-355.
  19. Mallett CL, Northrup NC, Saba CF, Rodriguez CO, Rassnick KM, Gieger TL, Childress MO, Howerth EW. Immunohistochemical characterization of feline mast cell tumors. Vet Pathol 2013; 50: 106-109. https://doi.org/10.1177/0300985812441032
  20. Miller MA, Nelson SL, Turk JR, Pace LW, Brown TP, Shaw DP, Fischer JR, Gosser HS. Cutaneous neoplasia in 340 cats. Vet Pathol 1991; 28: 389-395. https://doi.org/10.1177/030098589102800506
  21. Ozaki K, Yamagami T, Nomura K, Narama I. Prognostic significance of surgical margin, Ki-67 and cyclin D1 protein expression in grade II canine cutaneous mast cell tumor. J Vet Med Sci 2007; 69: 1117-1121. https://doi.org/10.1292/jvms.69.1117
  22. Preziosi R, Morini M, Sarli G. Expression of the KIT protein (CD117) in primary cutaneous mast cell tumors of the dog. J Vet Diagn Invest 2004; 16: 554-561. https://doi.org/10.1177/104063870401600610
  23. Rassnick KM, Williams LE, Kristal O, Al-Sarraf R, Baez JL, Zwahlen CH, Dank G. Lomustine for treatment of mast cell tumors in cats: 38 cases (1999-2005). J Am Vet Med Assoc 2008; 232: 1200-1205. https://doi.org/10.2460/javma.232.8.1200
  24. Rodriguez-Carino C, Fondevila D, Segales J, Rabanal R. Expression of KIT receptor in feline cutaneous mast cell tumors. Vet Pathol 2009; 46: 878-883. https://doi.org/10.1354/vp.08-VP-0084-R-FL
  25. Rogers KS. Mast cell disease. In: Textbook of veterinery internal medicine, 7th ed. St. Louis: Elsevier; 2010: 2193-2199.
  26. Romansik E, Reilly CM, Kass PH, Moore P, London CA. Mitotic index is predictive for survival for canine cutaneous mast cell tumors. Vet Pathol 2007; 44: 335-341. https://doi.org/10.1354/vp.44-3-335
  27. Sabattini S, Bettini G. Prognostic value of histologic and immunohistochemical features in feline cutaneous mast cell tumors. Vet Pathol 2010; 47: 643-653. https://doi.org/10.1177/0300985810364509
  28. Sabattini S, Frizzon MG, Gentilini F, Turba M, Capitani O, Bettini G. Prognostic significance of Kit receptor tyrosine kinase dysregulations in feline cutaneous mast cell tumors. Vet Pathol 2013; 50: 797-805. https://doi.org/10.1177/0300985813476064
  29. Simoes J, Schoning P, Butine M. Prognosis of canine mast cell tumors: a comparison of three methods. Vet Pathol 1994; 31: 637-647. https://doi.org/10.1177/030098589403100602
  30. Thompson J, Pearl D, Yager J, Best S, Coomber B, Foster R. Canine subcutaneous mast cell tumor characterization and prognostic indices. Vet Pathol 2011; 48: 156-168. https://doi.org/10.1177/0300985810387446
  31. Turrel JM, Farrelly J, Page RL, McEntee MC. Evaluation of strontium 90 irradiation in treatment of cutaneous mast cell tumors in cats: 35 cases (1992-2002). J Am Vet Med Assoc 2006; 228: 898-901. https://doi.org/10.2460/javma.228.6.898
  32. Vascellari M, Giantin M, Capello K, Carminato A, Morello E, Vercelli A, Granato A, Buracco P, Dacasto M, Mutinelli F. Expression of Ki67, BCL-2, and COX-2 in Canine Cutaneous Mast Cell Tumors Association With Grading and Prognosis. Vet Pathol 2013; 50: 110-121. https://doi.org/10.1177/0300985812447829
  33. Webster JD, Yuzbasiyan-Gurkan V, Kaneene JB, Miller R, Resau JH, Kiupel M. The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors. Neoplasia 2006; 8: 104-111. https://doi.org/10.1593/neo.05622
  34. Welle MM, Bley CR, Howard J, Rufenacht S. Canine mast cell tumours: a review of the pathogenesis, clinical features, pathology and treatment. Vet Dermatol 2008; 19: 321-339. https://doi.org/10.1111/j.1365-3164.2008.00694.x
  35. Zemke D, Yamini B, Yuzbasiyan-Gurkan V. Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Vet Pathol 2002; 39: 529-535. https://doi.org/10.1354/vp.39-5-529